InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,591.96
(
0.00%
)
US TECH 100
18,988.00
(
0.86%
)
Dow Jones
41,335.05
(
0.00%
)
Brent Oil
77.46
(
-1.66%
)
Bitcoin
59,558.03
(
0.28%
)
Post# of 252990
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 837
Posts 120347
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: dewophile post# 245650

Tuesday, 02/28/2023 5:49:57 PM

Tuesday, February 28, 2023 5:49:57 PM

Post# of 252990
PFE’s RSV vaccine_for_adults_60+_endorsed_by VRBPAC in_dual 7-4 votes_on_safety_and_efficacy:

https://finance.yahoo.com/news/pfizer-receives-positive-fda-advisory-214000244.html

The crux of the matter for the panel was whether the Guillain-Barre risk warrants another pre-approval trial or whether a post-approval trial, which PFE has consented to run, is sufficient.

PFE’s PDUFA date is 5/31/23.

VRBPAC debates GSK’s RSV vaccine tomorrow. (GSK has a PDUFA date of 5/3/23.)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up